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ABSTRACT: Background: Retinal optical coherence
tomography findings in Lewy body diseases and their implica-
tions for visual outcomes remain controversial. We investigated
whether region-specific thickness analysis of retinal layers
could improve the detection of macular atrophy and unravel its
association with visual disability in Parkinson’s disease.
Methods: Patients with idiopathic Parkinson’s disease
(n = 63), dementia with Lewy bodies (n = 8), and E46K muta-
tion carriers in the α-synuclein gene (E46K-SNCA) (n = 4) and
34 controls underwent Spectralis optical coherence tomog-
raphy macular scans and a comprehensive battery of visual
function and cognition tests. We computed mean retinal
layer thicknesses of both eyes within 1-, 2-, 3-, and 6-mm
diameter macular discs and in concentric parafoveal (1- to
2-mm, 2- to 3-mm, 1- to 3-mm) and perifoveal (3- to 6-mm)
rings. Group differences in imaging parameters and their rela-
tionship with visual outcomes were analyzed. A multivariate
logistic model was developed to predict visual impairment
from optical coherence tomography measurements in
Parkinson’s disease, and cutoff values were determined with
receiver operating characteristic analysis.
Results: When compared with controls, patients with
dementia with Lewy bodies had significant thinning of
the ganglion cell–inner plexiform layer complex within
the central 3-mm disc mainly because of differences in
1- to 3-mm parafoveal thickness. This parameter was
strongly correlated in patients, but not in controls, with
low contrast visual acuity and visual cognition outcomes
(P < .05, False Discovery Rate), achieving 88% of accu-
racy in predicting visual impairment in Parkinson’s
disease.
Conclusion: Our findings support that parafoveal thinning
of ganglion cell–inner plexiform complex is a sensitive and
clinically relevant imaging biomarker for Lewy body dis-
eases, specifically for Parkinson’s disease. © 2019 The
Authors. Movement Disorders published by Wiley Periodi-
cals, Inc. on behalf of International Parkinson and Move-
ment Disorder Society.
Key Words: dementia with Lewy bodies; macula; opti-
cal coherence tomography; Parkinson’s disease; visual
dysfunction
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Lewy body diseases (LBDs) encompass a spectrum of
disorders pathologically characterized by widespread
deposition of Lewy bodies in the central nervous sys-
tem. The most representative LBDs include aggressive
forms of idiopathic Parkinson’s disease (iPD), dementia
with Lewy bodies (DLB) and certain genetic variants of
Parkinson’s disease (PD), such as the E46K mutation in
the α-synuclein gene (E46K-SNCA),1 recognized as the
most pathogenic mutation-inducing PD.2 Besides the typi-
cal parkinsonian motor features, LBDs share several non-
motor manifestations involving impairment in cognition,
mood, sleep, autonomic function, pain perception, and
vision.3 Interestingly, vision-related manifestations are
frequent and determine a patient’s ability to perform
activities of daily living,4 being recognized as major pre-
dictors of cognitive deterioration in iPD.5
A recent landmark histopathological study demon-
strated that in iPD there is a preferential degeneration
of neurons within inner retinal layers (ganglion cell
layer [GCL], inner plexiform layer and inner nuclear
layer [INL]) associated with anomalous α-synuclein
deposits.6 Consistent with these findings, several in vivo
imaging studies with spectral-domain optical coherence
tomography (OCT) have demonstrated an atrophy of
macular GCL and the inner plexiform layer in iPD.7-14
Nevertheless, macular OCT studies in iPD have yielded
conflicting results because of the diversity of OCT
machines, image acquisition protocols, and segmentation
algorithms used. Interestingly, when applying mathemat-
ical models to analyze macular morphology, Bodis-
Wollner and colleagues found that iPD patients had a
specific pattern of macular thinning 0.5- to 2-mm eccen-
tric to the foveola.7,15,16
Considering that the extent of retinal injury in LBDs
might be subtle and selectively located within the central
macula, in the present study we evaluated whether the
distribution of retinal damage—measured by OCT—was
related to visual disability in LBDs, particularly in iPD
patients.
Material and Methods
Participants and Study Design
We performed a cross-sectional study of 75 patients
with LBDs, including iPD (n = 63), DLB (n = 8) and
symptomatic E46K-SNCA carriers (n = 4), and 34 con-
trols. Controls were selected to approximately match
the E46K-SNCA carriers in age and sex. Participants
were recruited through the Department of Neurology at
Cruces University Hospital and the Biscay PD Associa-
tion (ASPARBI). Patients with iPD fulfilled Parkinson’s
UK Brain Bank criteria for the diagnosis of PD and
patients with DLB had a diagnosis of probable DLB by
2016 revised criteria for the clinical diagnosis of DLB.
All patients were studied in an on-medication condition
to complete all study assessments.
The study protocol was approved by the regional
Basque Clinical Research Ethics Committee. All partici-
pants gave written informed consent prior to their par-
ticipation in the study, in accordance with the tenets of
the Declaration of Helsinki.
Demographical and PD-Related Features
Age, sex and years of education were recorded for all
participants. Two neurologists experienced in the field of
movement disorders recorded disease duration, Hoehn &
Yahr Scale score, Unified Parkinson’s Disease Rating
Scale part III (motor examination) scores (UPDRS III),
and Levodopa Equivalent Daily Dose (LEDD).
Visual Outcome Assessment
A protocol was designed for the screening of ocular
conditions and overall cognitive status in all candidates
(see Supplementary Material). Primary vision measure-
ments were obtained binocularly with best-corrected
refraction. We registered high- and low-contrast visual
acuities as the total number of letters correctly identified
in, respectively, standard Early Treatment Diabetic Reti-
nopathy Study (ETDRS) charts and Sloan 2.5% charts
(Precision Vision, La Salle, Illinois, USA) mounted in a
retro-illuminated cabinet at 4 meters. Contrast sensitivity
was measured with a Pelli-Robson chart at 1 meter under
photopic conditions (280 lux), and the lowest contrast at
which 2 letters in a triplet were correctly identified was
recorded. For color vision testing, we used the Hardy
Rand and Rittler pseudoisochromatic plates and the Roth
28 (R28) hue test.
In addition, we performed a detailed evaluation of
visual cognition with a battery of neuropsychological
tests grouped into the following 4 domains: (1) visual
attention and processing speed, based on the results
from the Salthouse Perceptual Comparison Test (cor-
rect answers), Trail Making Test part A (inverse of the
time to complete the test), and Symbol Digit Modali-
ties Test (number of correct answers); (2) visual
memory, measured by the Brief Visual Memory Test-
Revised (total score + delayed recall); (3) visual per-
ception, based on the number of correct answers in the
Picture Completion subtest of the Wechsler Adult
Intelligence Scale IV, Benton Judgement of Line Orien-
tation Test (H-form), and Number Location and Cube
Analysis tests of the Visual Object and Space Percep-
tion battery; and (4) visual construction, consisting of
the Clock Drawing Test (Rouleau scoring method). All
neuropsychological outcome variables were converted
to z-scores and averaged to create a composite score
for each visual cognition domain. The internal consis-
tency of each composite score was examined by
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calculating Cronbach’s α, and this was found to be
above 0.85 in all cases.
OCT Acquisition, Segmentation,
and Processing
We obtained macular volumetric images with a Spec-
tralis spectral-domain OCT system (Heidelberg Engi-
neering, Heidelberg, Germany). All macular scans were
centered on the fovea and consisted of 25 single horizontal
axial scans covering a 20 x 20 area, with 512 A-scans per
B-scan, and 49 frames were averaged per B-scan (auto-
matic real-time tracking: 49). All acquisitions were
obtained by the same experienced operator, and the built-
in tracking system was used to compensate for eye move-
ments. All OCT images fulfilled quality control criteria
from OSCAR-IB consensus, accounting for Obvious prob-
lems (O), poor Signal strength (S), Centration of scan (C),
Algorithm failure (A), Retinal pathology other than PD-
related (R), Illumination (I) and Beam placement (B).17 The
built-in software of the Spectralis OCT equipment (HRA
Spectralis Viewing Module version 6.0.9.0) automatically
segmented macular layers, and the thickness measures
were calculated for the combinations of layers and regions
illustrated in Figure 1A,B. Following Advised Protocol for
OCT Study Terminology and Elements (APOSTEL)
recommendations,18 the measurements of both eyes were
averaged to account for intereye within-patient dependen-
cies unless any pathological condition affected one of the
eyes, in which case only the healthy eye was included in the
analysis.
Statistical and Classification Analyses
Statistical analyses were carried out using IBM SPSS Sta-
tistics for Windows, version 20.0 (IBM-SPSS, Armonk,
New York). Continuous variables were assessed for nor-
mality with the Shapiro–Wilks test. Categorical variables
were computed with pairwise Fisher’s exact tests, and the
differences in continuous variables were analyzed using
the Mann–Whitney U test for pairwise comparisons or
Kruskal–Wallis analysis of variance with Dunn’s post hoc
test for multiple-group comparisons.We calculated partial
correlations between OCT measurements and visual out-
comes, controlling for age. Correction for multiple com-
parisons was performed via False Discovery Rate. Next,
we classified LBD patients into 2 groups based on visual
outcomes using unsupervised K-means clustering algo-
rithm with a predefined number of 2 clusters (scikit-learn
package [https://scikit-learn.org] running under Python
3.7 [https://www.python.org/]), and we evaluated with
univariate logistic regression the significance of the associ-
ation between OCT parameters and visual impairment
status in iPD. The P values of significant predictors were
corrected with the Bonferroni method for multiple com-
parisons. In addition, to account for the effect of age on
retinal atrophy,19 we performed a multivariate logistic
regression analysis including both age and individual
OCT measures. Then, we used the estimated probabilities
to create receiver operating characteristic curves, calcu-
lated as P = 1/[1 + e^ (−y)], where ‘y’ corresponds to the
fitted model resulting from the logistic regression. The





The general characteristics of the study participants are
displayed in Table 1. The patients were predominantly
men (65.3%) and relatively young (mean, 62.96 years
old). We did not observe significant differences in terms
of sex or years of education between the controls and
patients, but those with DLB were significantly older than
other patient groups and controls. Patients’ mean disease
duration was 6.49 years, and they had mild to moderate
bilateral motor disability (mean UPDRS III, 27.04;
median Hoehn & Yahr score, 2.5), without significant
differences between groups. Overall cognitive perfor-
mance was significantly lower in patients than in controls
and in DLB patients when compared with iPD patients.
Primary Visual Function and Visual Cognition
As shown in Table 1, primary visual function was
significantly worse in patients than in controls, mainly
low-contrast visual acuity, which was severely impaired
in the E46K-SNCA and DLB patients and moderately
impaired in iPD patients. Regarding visual cognition
scores, patients also performed worse than controls.
E46K-SNCA and DLB patients showed the most mar-
ked differences with respect to controls, especially for
visual attention and processing speed domain, whereas
E46K-SNCA patients also performed significantly worse
than iPD patients in the visual construction domain.
Macular Layer Thickness
When patients where compared as a single group with
controls, the differences in retinal layer thicknesses that
reached statistical significance were primarily within the
range of 1 to 2 μm, which is below the 3.9-μm axial reso-
lution of Spectralis OCT (Supplementary Table 1). When
individual patient groups were compared separately with
controls, we identified a tendency for inner retinal layer
thinning in LBD patients with aggressive phenotypes,
especially in areas within the 3-mm diameter disc. When
compared with controls, ganglion cell-inner plexiform
layer complex (GCIPL) was significantly thinner in
patients with DLB (−10.88 μm, P = .002), and INL was
significantly thinner in the E46K-SNCAmutation carriers
(−3.72 μm, P = .02). Interestingly, the thinning of the
GCIPL in DLB was significant for all subdivisions of the
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FIG. 1. (A) A funduscopic image with superimposed foveola-centered 1-, 3-, 6-mm diameter and 1-, 2-, 3-mm diameter Early Treatment Diabetic Retinopa-
thy Study (ETDRS) grids provided by the Spectralis optical coherence tomography (OCT) (above). Dotted lines delimitate foveal, parafoveal, and perifoveal
boundaries in a transversal macular OCT section (below), in which colors represent the set of macular layers and/or layer complexes analyzed for the present
study. (B) Macular regions used for calculating mean layer thicknesses of both eyes. (C) Combined violin- and box-plots with individual data points of each
diagnostic group for the distribution of mean GCIPL thicknesses of 6-mm disc (left), 3- to 6-mm ring (middle), and 3-mm disc (right). Dashed lines indicate
highest and lowest median GCIPL thickness values for all groups within each plot. (D) Age-adjusted partial correlations between mean GCIPL thicknesses in
different macular regions and visual outcomes in control participants (above) and iPD patients (below). Only macular parameters that were statistically signifi-
cant (P < .05) in partial correlations are shown in color. Asterisks represent correlations that remained statistically significant after False Discovery Rate (FDR)
adjustment of P values for multiple comparisons. CS, contrast sensitivity; DLB, dementia with Lewy bodies; E46K-SNCA, carriers of E46K mutation in
α-synuclein gene; ELM-BM, the complex including external limiting membrane, ellipsoid band, retinal pigment epithelium and Bruch membrane; GCIPL, gan-
glion cell–inner plexiform layer complex; HC, healthy controls; HCVA, high-contrast visual acuity; INL, inner nuclear layer; iPD, idiopathic Parkinson’s dis-
ease; LCVA, low-contrast visual acuity; mRNFL, macular retinal nerve fiber layer; OPL-HF-ONL, outer plexiform–Henle fiber–outer nuclear layer complex;
R28, Roth 28 hue test; VAPS, visual attention and processing speed composite; VCON, visual construction composite; VMEM, visual memory composite;
VPER, visual perception composite; FDR, False Discovery Rate. [Color figure can be viewed at wileyonlinelibrary.com]
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3-mm disc except the fovea (1-mm disc), suggesting a selec-
tive thinning of the parafovea in DLB. Following a similar
distribution, GCIPL and INL were significantly thinner in
the DLB and E46K-SNCA patients, respectively, than in
the iPD patients. Contrarily, the ELM-BM layer complex
(see Figure 1) within the 3- to 6-mm and 2- to 3-mm rings
was significantly thicker in the E46K-SNCA mutation car-
riers when compared with controls and iPD patients, but
the average differences were below 4 μm.
Association Between Regional Thickness
of Macular Layers and Visual Outcomes
We first analyzed age-corrected correlations between
macular thickness measures and primary visual func-
tion and visual cognition parameters in LBD patients
and controls separately. While correlations for the 3- to
6-mm ring measures (perifovea) yielded practically non-
significant results, the correlations for the disc and ring
thicknesses of GCIPL within the 3-mm area were posi-
tive and markedly significant in patients. In fact, we
observed that, after False Discovery Rate correction,
the most central area of the macula (3-mm disc) was the
region with the highest number of significant correlations
with visual outcomes, specifically with low-contrast
visual acuity, visual attention and processing speed and
visual perception. The former correlation pattern persisted
when the 1- to 3-mm ring (parafovea) was analyzed alone,
whereas foveal GCIPL thickness (1-mm disc) did not corre-
late with visual function. Interestingly, GCIPL thickness in
the parafoveawas also the parametermost frequently corre-
lated with visual outcomes in iPD patients (Figs. 1D and 2).
Furthermore, in univariate regression analysis, we con-
firmed that the selective atrophy of 1- to 3-mm GCIPL ring
was the single best predictor of visual dysfunction in
patients with iPD (Table 2). The correlations of visual func-
tions with INL thickness were statistically significant within
the 3-mmdisc, but theywere limited to visual cognitive abil-
ities when all LBD patients were considered, losing signifi-
cance when only iPD were assessed. It is worth mentioning
that outer plexiform–Henle fiber–outer nuclear layer mean
thickness within the 1-mm disc was highly correlated with
low-contrast visual acuity and visual attention and
processing speed in patients, even when iPD patients were
analyzed separately. No other parameter from external reti-
nal layers was found to be significantly correlated with
visual function.None of the former associationswere found
in control participants (Fig. 1D).
Because 1- to 3-mm ring (parafoveal) GCIPL thickness
was the retinal parameter that presented the greatest atro-
phy in DLB patients and the best correlation with visual
dysfunction in iPD patients, we used the latter measure
for dividing iPD patients into 3 groups using tertiles to
illustrate the exposure–response relationship between
GCIPL atrophy and visual dysfunction (Fig. 2). The
median GCIPL thickness of middle tertile was equivalent
TABLE 1. Demographics, PD characteristics, primary visual function and visual cognition for each diagnostic category
Variables, units Control All patients P iPD E46K-SNCA DLB P
Demographics and PD characteristics
n 34 75 63 4 8
Age, years 59.79 (6.22) 62.96 (9.11) .036 61.91 (8.56) 57.58 (5.27) 73.92 (7.29) .001a
Males, n (%) 16 (47.1) 49 (65.3) .266 41 (65.1) 2 (50.0) 6 (75.0) .208b.c
Education, years 12.50 (3.98) 11.04 (4.28) .121 10.97 (4.28) 14.75 (2.63) 9.75 (4.23) .089
Disease duration, years NA 6.49 (4.10) NA 6.15 (3.77) 8.81 (5.15) 7.98 (5.76) .454
Hoehn & Yahr score NA 2.5 (1.0-4.0) NA 2.0 (1.0-4.0) 2.5 (0.0-3.0) 2.5 (2.0-3.0) .108
UPDRS III total score NA 27.04 (11.92) NA 25.76 (10.67) 28.25 (20.37) 37.14 (13.74) .052
LEDD, mg/day NA 657.56 (396.70) NA 666.70 (384.30) 800.38 (701.56) 514.13 (329.71) .663
MoCA total score 26.56 (2.43) 23.05 (4.60) <.001 24.02 (3.24) 19.00 (6.98) 17.63 (7.52) <.001d.e
Primary visual function
High-contrast VA, # correct letters 62.53 (4.23) 57.93 (7.10) <.001 59.50 (5.01) 52.75 (3.59) 48.38 (12.13) <.001d.f
Low-contrast VA, # correct letters 38.29 (6.32) 25.61 (12.44) <.001 27.92 (11.28) 11.50 (13.89) 15.38 (11.65) <.001d.f
Contrast sensitivity, log units 2.04 (0.15) 1.90 (0.15) <.001 1.91 (0.15) 1.84 (0.07) 1.84 (0.19) <.001d
HRR color vision, # correct symbols 36.00 (0.00) 35.14 (2.06) .003 35.62 (1.23) 34.00 (1.41) 32.25 (4.06) <.001e.g
R28 hue color vision test, TES 47.54 (53.93) 101.52 (130.49) .464 84.54 (129.62) 117.00 (104.79) 244.00 (46.58) .005b.e
Visual cognition composite scores
Visual attention and processing
speed
0.53 (0.61) −0.28 (0.91) <.001 −0.10 (0.83) −1.26 (0.83) −1.38 (0.50) <.001d.f
Visual memory 0.47 (0.39) −0.24 (0.84) <.001 −0.15 (0.81) −1.12 (1.00) −0.67 (0.58) <.001h
Visual perception 0.64 (0.52) −0.32 (1.00) <.001 −0.23 (0.97) −0.58 (1.34) −1.04 (0.95) <.001d
Visual construction 0.49 (0.55) −0.25 (1.09) <.001 −0.09 (0.94) −2.15 (1.39) −0.58 (1.20) <.001d.i
The results are displayed as mean (standard deviation) except for sex and Hoehn & Yahr score, which are shown, respectively, as number of males (% of males)
and as median (range). The results for visual cognition composite scores are quantified as z-scores. Statistically significant results (P < .05) in post hoc
group-wise comparisons (see Methods section) are indicated as the following: (a) DLB vs control, iPD and E46K-SNCA; (b) E46K-SNCA vs DLB; (c) control vs
iPD; (d) control vs iPD, E46K-SNCA and DLB; (e) iPD vs DLB; (f ) iPD vs E46K-SNCA and DLB; (g) control vs E46K-SNCA and DLB; (h) control vs iPD and DLB; (i)
iPD vs E46K-SNCA. DLB, dementia with Lewy bodies; E46K-SNCA, patients with E46K mutation in α-synuclein (SNCA) gene; HRR, color vision with Hardy Rand
and Rittler pseudoisochromatic plates; iPD, idiopathic Parkinson’s disease; LEDD, Levodopa Equivalent Daily Dose; MoCA, Montreal Cognitive Assessment; NA,
nonapplicable; TES, Total Error Score; UPDRS III, Unified Parkinson’s Disease Rating Scale part III; VA, visual acuity.
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to that in controls, and median parafoveal GCIPL thick-
ness of the lower tertile was similar to that in DLB
patients (Supplementary Table 2). iPD tertiles did not dif-
fer in disease duration (Kruskal–Wallis, P = .283) or
motor impairment (P = .279), but patients in the lower
tertile were significantly older (Kruskal–Wallis, P = .001).
Accuracy of Parafoveal GCIPL Thickness
to Identify Visually Impaired PD Patients
Clustering analysis identified 16 of 57 iPD patients as
visually impaired because theywere grouped together with
patients from aggressive phenotype groups (DLB and
E46K-SNCA; Fig. 3). The receiver operating characteristic
curve analysis of estimated probabilities showed that the
predictive accuracy of 1- to 3-mmGCIPL thickness alone
or in combination with age was high (Table 2 and Fig. 3).
The area under the curve of the univariate model was
0.85 (P < .001; 95% confidence interval, 0.738-0.962;
standard error, 0.057), and the optimal cutoff value of
estimated probability was 0.35 (sensitivity, 81.3%; speci-
ficity, 85.4%; Youden’s Index, 0.66). When age was
added as an independent predictor to the model, the area
FIG. 2. Scatterplots representing the relationship between 1- to 3-mm mean GCIPL thickness and visual outcomes in iPD patients. Individual dots of
scatter plots have been color-coded according to iPD tertiles obtained from 1- to 3-mm mean GCIPL thickness distribution: blue for upper tertile (T1),
orange for middle tertile (T2) and green for lower tertile (T3). A combined violin- and box-plot for 1- to 3-mm mean GCIPL thickness distribution dis-
playing iPD tertiles is shown in the upper left corner. Visual outcomes are provided in z-scores. R2 represents the proportion of the variance explained
for each individual visual outcome by GCIPL thickness. Only False Discovery Rate (FDR)-adjusted significant correlations are plotted. GCIPL, ganglion
cell–inner plexiform layer complex; iPD, idiopathic Parkinson’s disease. [Color figure can be viewed at wileyonlinelibrary.com]
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under the curve increased to 0.88 (P < .001; 95% confi-
dence interval, 0.779-0.971; standard error, 0.049), and
the optimal cutoff value was 0.44 (sensitivity, 81.3%;
specificity, 90.2%; Youden’s Index, 0.72; Fig. 3). The
accuracy of the multivariate model (88%) was higher
than the baseline accuracy of 72% (determined by the
prevalence of visually unaffected iPD). When we repeated
this process to determine whether 1- to 3-mm GCIPL
thickness alone or in combination with age could discrimi-
nate control participants from iPD patients, the area under
the curve was below 0.61 (P > .05), and there was no
improvement in the classification accuracy when com-
pared with baseline accuracy (64%). These results suggest
that GCIPL thickness in the parafovea is a suitable param-
eter for identifying iPD patients with visual impairment,
but not for discriminating healthy controls from iPD.
Discussion
To our knowledge, this is the first study evaluating the
influence that the specific distribution of retinal injury in
LBDs has on a wide range of primary vision and visual
cognition outcomes measured, respectively, with high-
resolution OCT images and a comprehensive battery of
visual function and neuropsychological tests. Moreover,
our study supports the view that selective atrophy of
GCIPL in the parafoveal region (1- to 3-mm ring) is a
major contributor to visual disability in LBD patients and
may help to identify iPD patients with severe visual
impairment. Interestingly, thickness measurements in the
perifoveal region (3- to 6-mm ring) were not correlated
with visual outcomes in patients, a finding that further
highlights the specificity of macular damage in the most
central and parafoveal regions in LBDs.
Several studies have evaluated retinal thickness using
OCT in iPD and other parkinsonian syndromes. Most
publications used standard 6-mm diameter ETDRS
grids to compute overall macular measurements of the
entire retina and/or selected macular layers. ETDRS
grids divide the macula into foveola-centered concentric
circular subfields of 1, 3, and 6 mm in diameter, and
3- and 6-mm rings are further divided into superior, infe-
rior, temporal, and nasal sectors. Altintas and colleagues20
first reported that macular volume and thickness were
reduced in patients with iPD, except in the fovea. Similarly,
the following year, Hajee and colleagues21 observed a signif-
icant thinning of inner retinal layers in the superior and infe-
rior sectors of the macula, but failed to find differences in
outer retinal layers. Despite that early evidence on retinal
thinning in iPD, several subsequent studies have provided
conflicting results.Whereas some authors have reported that
iPD patients have a significant and marked thinning of the
macula10,12-14 and its inner retinal layers,8,9,11,21-26 others
have evidenced outer retinal layer thinning,27 or even
thickening,11,24 and some have failed to find any differ-
ences.28-34 The variability in scanning protocols, acquisition
parameters and built-in segmentation algorithms across dif-
ferent OCT systems is a well-established limitation for com-
paring the results of different studies35 and could account
for the discrepancies found in the literature regarding retinal
alterations in iPD. Specifically, the differences in acquisi-
tion speed and axial resolution between time-domain
and spectral-domain OCTs might explain why studies
using older time-domain OCT devices (eg, Stratus) only
detected significant differences between iPD patients and
controls when absolute differences in thickness were
greater than 10 μm,20,36 whereas studies using spectral-
domain OCTs have yielded significant results with differ-
ences from 2 to 7 μm in thickness regardless of the area
analyzed,7,9,12,24,25,27,34,37-40 which is consistent with the
magnitude of inner retinal thinning observed in our E46K-
SNCA cohort. Some authors have found even greater thin-
ning (11 to 19 μm) of selected ETDRS sectors in iPD
patients,10,22,23 but none of them reported disease dura-
tion or measures of disease severity (eg, motor scales),
meaning that we are unable to ascertain whether the latter
OCT findings could be ascribed to longer disease duration
or more severe disease, as we found in the present study
for themost aggressive LBDs (DLB and E46K-SNCA).
Another important factor that might underline the
discrepancies between OCT studies in iPD relates to the
retinal areas and layers for which macular measures
were obtained.41 For example, the RTVue-100 OCT
(Optovue Inc., Fremont, CA, USA) calculates the aver-
age thickness of the inner retinal layers (retinal nerve
fiber layer, GCL, and IPL) within foveola-centered
5-mm, 6-mm, or 7-mm diameter circular grids, whereas
the Spectralis OCT provides the average thickness per
TABLE 2. Coefficients of regression models for significant
predictors of visual impairment in patients with
Parkinson’s disease
Univariate model Constant (β0) β
Bonferroni-
adjusted P
3-mm GCIPL thickness 16.16 −0.20 .007
2-mm GCIPL thickness 13.46 −0.19 .008
1- to 3-mm GCIPL thickness 16.93 −0.20 .006
1- to 2-mm GCIPL thickness 13.52 −0.17 .006
2- to 3-mm GCIPL thickness 13.53 −0.15 .030
Multivariate model β SE P
Constant 4.98 6.99 .476
1- to 3-mm GCIPL thickness −0.15 0.06 .007
Age 0.13 0.06 .041
Univariate regression analysis of optical coherence tomography measure-
ments revealed GCIPL thickness variables within the central 3 mm of the mac-
ula as significant predictors of visual disability in Parkinson’s disease patients,
after correcting P values for multiple comparisons with the Bonferroni method.
Concretely, from the overlapping optical coherence tomography variables, the
mean GCIPL thickness in a 1- to 3-mm ring was found to be the most relevant
variable. Multivariate regression analysis showed that age also acted as a sig-
nificant predictor of visual dysfunction. β, beta coefficient resulting from logis-
tic regression; GCIPL, ganglion cell–inner plexiform layer; SE, standard error.
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layer in each sector of the 1-, 3-, and 6-mm ETDRS grid,
and the Cirrus OCT (Carl Zeiss Meditec AG, Jena,
Germany) computes GCL and IPL thickness as a single
measure and provides the mean values of the 6 sectors
within an elliptical annulus around the fovea. Despite the
differences in OCT devices and acquisition protocols, our
findings are consistent with the results of several other
studies, supporting the view that the parafoveal region of
the macula is specifically affected in iPD and the hypothe-
sis of foveal pit remodeling in iPD.7,15,16,39,42 Intriguingly,
in all of the studies that have failed to find differences
between iPD patients and controls, the analyses were lim-
ited to computing whole macular thickness,28,29,32,37 over-
all macular volumes,27,31 or average inner retinal layer
thickness24,29-33 in a 6-mm diameter disc without further
topographical analysis, which may have masked significant
focal retinal differences. Spund and colleagues7 reported
that the major difference in retinal thickness between con-
trols and iPD patients was found between 0.5- and 2-mm
eccentric to the foveola. In accordance with those findings,
our data indicated that macular layer thinning of inner ret-
inal layers occurred in DLB and E46K-SNCA groups, and
this was evident when using the average thicknesses
obtained from the 3-mm disc, suggesting that macular
changes in LBDs might exclusively occur in the most cen-
tral regions. As we report in this work, 6-mm disc average
measures are highly influenced by values from the external
3- to 6-mm ring, masking the differences that are mainly
present within the central 3 mm of the macula.
Regarding the relationship between retinal parameters
and functional outcomes, some studies have claimed that
the pattern of retinal thinning is associated with a longer
FIG. 3. Upper panel, visual function–based clustering of patients. Middle panel, logistic regression analysis to assess the predictive ability of 1- to
3-mm GCIPL thickness in differentiating iPD patients with visual dysfunction from visually unaffected iPD patients as a single predictor (dashed red line)
or in combination with age (continuous red line). Lower panel, receiver operating characteristic (ROC) curve. Estimated probabilities resulting from logis-
tic regression were used as classifiers. The “X” inside the ROC curve indicates the cutoff point of multivariate analysis that corresponds to an estimated
probability of 0.44. The individual probability can be calculated using the following formula: P = 1 / [1 + e^ (−4.98 + 0.15[parafoveal GCIPL thickness]
− 0.13(age)]. Patients with probabilities above the cutoff value are considered to have visual dysfunction. AUC, area under the curve; DLB, dementia
with Lewy bodies; E46K-SNCA, carriers of E46K mutation in α-synuclein gene; GCIPL, ganglion cell–inner plexiform layer complex; iPD, idiopathic
Parkinson’s disease. [Color figure can be viewed at wileyonlinelibrary.com]
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duration and clinical severity of the disease.7,8,43 However,
we found that disease duration and motor impairment
were comparable across iPD patients with different degrees
of parafoveal GCIPL atrophy, suggesting that retinal atro-
phy might be present from the early stages. Moreover, the
fact that a significant thinning of the inner retinal layers
was only present in the DLB and E46K-SNCA groups may
indicate that the loss of inner retinal cells predominantly
occurs in patients with aggressive phenotypes. A similar
idea has also emerged from brain imaging studies, in which
more pronounced gray matter loss has been found in indi-
viduals with aggressive LBDs than in those with iPD or
healthy controls,44,45 suggesting that this difference in tis-
sue loss may help identify iPD patients with a worse prog-
nosis. It is important to underline that so far, few studies
have evaluated the association between OCT measures
and primary vision or visual cognition in LBDs. Polo and
colleagues38 reported that overall macular thinning in PD
patients was correlated with worse low-contrast visual acu-
ity, contrast sensitivity and color vision, whereas Miri and
colleagues46 observed that only the thinning of the par-
afoveal region correlated with contrast sensitivity. Our
work extends the data far beyond those observations,
showing that central macular parameters, especially those
for the parafoveal region, are significantly associated with
visual outcomes measured by a comprehensive set of pri-
mary vision and visual cognition tests. Even though we
also found that foveal (1-mm disc) outer plexiform–Henle
fiber–outer nuclear layer thickness was highly correlated
with visual outcomes, the lack of detectable thickness dif-
ferences between controls and LBD patients make this
parameter less interesting as a biomarker for PD.
To date, it is not known why retinal thinning takes
place in LBDs, and there is no satisfactory pathophysio-
logical explanation of the observed selective changes in
the parafoveal inner retinal layers, while the other macu-
lar layers and areas seem to remain unaltered. Preclinical
studies have provided some insights into the morphologi-
cal retinal impairment in iPD, where a loss of dopaminer-
gic network and synaptic contacts with amacrine cells has
been observed.47 As the extent of GCIPL thinning is for
some iPD patients lower than the thickness of a single cell
body, a loss of the dendritic network in the inner retinal
layers could be a plausible explanation in such cases.
Potential limitations of the current study include the
smaller sample sizes of DLB and E46K-SNCA groups and
the older DLB group. First, it was challenging to identify
patients fulfilling probable DLB criteria that were able to
complete all study assessments. Second, genetic PD vari-
ants, including E46K-SNCA, are rare and limited to spe-
cific families and series around the world. We believe the
effects of sample size and age differences were mitigated by
using Kruskal–Wallis, a robust statistical test for the het-
erogeneity of variances, and by controlling for age in corre-
lation analyses. Another potential limitation of our study is
that, given its exploratory nature, we did not correct for
multiple testing when computing group differences in mac-
ular thicknesses for areas with different eccentricities. Like-
wise, it is reasonable to suppose that, in addition to retinal
alterations, patients with LBDs may have abnormalities at
any level of the visual pathway or visual associative areas,
as demonstrated by quantitative structural, functional and
metabolic brain magnetic resonance imaging,48-50 and
such abnormalities may further contribute to visual impair-
ment. Finally, in the multivariate classification strategy, we
provide cutoff values to estimate the individual probability
of iPD patients for presenting visual impairment. Although
age incremented the accuracy of the model, the assumption
of independence of predictors may not hold true, and the
data must be interpreted with caution.
In conclusion, the present work represents an innovative
approach for understanding the impact of the distribution
of retinal injury on visual outcomes in patients with LBDs,
demonstrating that selective atrophy of GCIPL in the par-
afoveal region, observable with spectral-domain OCT,
might be a key contributor to visual disability. Further-
more, given that OCT provides noninvasive, fast, and
highly reproducible measures, our results may ultimately
have practical implications for the screening of nonmotor
disabilities in iPD patients.
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